LTRN - Lantern Pharma Inc

https://www.lanternpharma.com

Momentum: Bearish

Recent News

Lantern Pharma ( NASDAQ:LTRN ) , a biotech focused on AI-enabled precision oncology, released its earnings for the quarter ended June 30, 2025, on August 13, 2025. Lantern Pharma reported a GAAP net loss per share of ( $0.40 ) in Q2 2025, and marking an improvement from ( $0.46 ) per share ( GAAP ...

Neutral

IBN Initiates Coverage of Lantern Pharma Inc. - Lantern Pharma ( NASDAQ:LTRN )

Benzinga • 1 month, 4 weeks ago • score: 0.09

AUSTIN, Texas, July 16, 2025 ( GLOBE NEWSWIRE ) -- via IBN -- Lantern Pharma Inc.

Neutral

EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients - Lantern Pharma ( NASDAQ:LTRN )

Benzinga • 4 months ago • score: 0.12

The study will assess safety, preliminary efficacy, and biomarker correlations, potentially paving a path toward accelerated development. The biomarker-focused trial will target high-risk NSCLC subtypes by evaluating LP-184 in combination with Bristol-Myers' drugs.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics, and machine learning. The company is headquartered in Dallas, Texas.

52W High

$6.12

52W Low

$2.55

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.47

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.21

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

3.72

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

14.09%

Institutions (25–75% balanced)

20.97%

Shares Outstanding

10,799,400

Float

8,202,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-1.78

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.89%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.1306

-0.1086

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025